Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab

Not Applicable

Active, not recruiting

Interventions: Other: placebo
Drug: menadione topical lotion
Other: questionnaire administration
Procedure: management of therapy complications

Brief Summary: This clinical trial studies menadione topical lotion in treating skin discomfort and psychological distress in patients with cancer receiving panitumumab, erlotinib hydrochloride, or cetuximab. Menadione topical lotion may prevent rash or other skin discomfort and help alleviate psychological distress and pain in patients receiving treatment with panitumumab, erlotinib hydrochloride, or cetuximab

Detailed Description: PRIMARY OBJECTIVES:

I. Explore the effectiveness of a menadione topical lotion to the face to prevent cutaneous and psychological discomfort from epidermal growth factor receptor (EGFR) inhibitors.

SECONDARY OBJECTIVES:

I. Explore the adverse event profile of a menadione topical lotion to the face to prevent rash from EGFR inhibitors.

II. Explore whether rash or adverse events worsen over a 4 week period after this 4-week intervention.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients apply menadione topical lotion twice daily (BID) for 28 days.

ARM II: Patients apply topical placebo lotion BID for 28 days.

After completion of study treatment, patients are followed up for 4 weeks.

Recruitment & Eligibility

Inclusion Criteria

Age 18 years or older.
Patient scheduled to start an epidermal growth factor receptor inhibitor (must be one of these three: panitumumab, erlotinib, cetuximab) within the next 3 days or patient has already started the epidermal growth factor receptor inhibitor but has not been on it for longer than 3 days and has no signs or symptoms potentially suggestive of EGFR inhibitor toxicity.
Ability to reliably apply Menadione Topical Lotion / placebo twice a day to the face.
Ability to complete questionnaire(s) by themselves or with assistance.
Negative pregnancy test (serum or urine) done ≤ 7 days prior to registration, for women of childbearing potential only.
Willing to have photographs taken to assess rash.

Exclusion Criteria

Any active facial and/or chest rash, including adult acne, at the time of randomization.
Cutaneous metastases, skin cancer, or a history of precancerous skin lesions involving the face and/or chest.
Use of topical corticosteroids on the face and/or chest at the time of study entry or their anticipated use in the next 8 weeks.
Any type of ongoing therapy for rash.
Any of the following:
- Pregnant women
- Nursing women
- Men or women of childbearing potential who are unwilling to employ adequate contraception since this study involves agents that have known genotoxic, mutagenic and teratogenic effects
Use of any antibiotic at the time of study or their anticipated use in the 8 weeks immediately following study enrollment.

Arm && Interventions

Group	Intervention	Description
Arm II (placebo)	placebo	Patients apply topical placebo lotion BID for 28 days.
Arm I (lotion)	questionnaire administration	Patients apply menadione topical lotion BID for 28 days.
Arm I (lotion)	menadione topical lotion	Patients apply menadione topical lotion BID for 28 days.
Arm I (lotion)	management of therapy complications	Patients apply menadione topical lotion BID for 28 days.
Arm II (placebo)	questionnaire administration	Patients apply topical placebo lotion BID for 28 days.

Primary Outcome Measures

Name	Time	Method
Change From Baseline to Week 4 Face Pain Score Measuring Cutaneous Discomfort	From Baseline to Week 4	Change from baseline to Week 4 Face pain score measuring cutaneous discomfort. Face pain scale question ("How would you describe how your face feels?") with a 0-10 Face Pain Scale, where 0 = No pain/burning and 10 = worst possible pain/burning.

Secondary Outcome Measures

Name	Time	Method
Long-term Psychosocial Discomfort as Measured by the Change From Baseline in Psychological Distress Score at 4 Weeks (Treatment-regimen Estimand)	Baseline, Week 4	Least Squares mean (LS) of the Psychological Distress Score change from baseline at week 4 was adjusted by treatment, week, race, gender, age (\<=50 years/\>50 years), and EGFR, via a MMRM analysis. Psychological Distress question ("How often have you been bothered by embarrassment about your face?") with a 0-6 scale, where 0 = Never bothered and 6 = Always bothered.
Long-term Cutaneous Discomfort as Measured by the Change From Baseline in Face Pain Scale at 4 Weeks (Treatment-regimen Estimand)	Baseline, 4 weeks	Least Squares mean (LS) of the Face Pain Scale change from baseline at week 4 was adjusted by treatment, week, race, gender, age (\<=50 years/\>50 years), and EGFR, via a MMRM analysis. Face pain scale question ("How would you describe how your face feels?") with a 0-10 Face Pain Scale, where 0 = No pain/burning and 10 = worst possible pain/burning.
The Number of Patients Experiencing Worst Toxicity	Up to 8 weeks	The number of patients experiencing treatment-related adverse events (toxicities) is reported below. The maximum grade toxicity (worst toxicity) is reported by arm.

Locations (2): Mayo Clinic
🇺🇸
Rochester, Minnesota, United States
Mayo Clinic Campus in Arizona
🇺🇸
Phoenix, Arizona, United States